Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Andre Bollacke"'
Autor:
Faten Alchab, Laurent Ettouati, Zouhair Bouaziz, Andre Bollacke, Jean-Guy Delcros, Christoph G.W. Gertzen, Holger Gohlke, Noël Pinaud, Mathieu Marchivie, Jean Guillon, Bernard Fenet, Joachim Jose, Marc Le Borgne
Publikováno v:
Pharmaceuticals, Vol 8, Iss 2, Pp 279-302 (2015)
Due to their system of annulated 6-5-5-6-membered rings, indenoindoles have sparked great interest for the design of ATP-competitive inhibitors of human CK2. In the present study, we prepared twenty-one indeno[1,2-b]indole derivatives, all of which w
Externí odkaz:
https://doaj.org/article/b7da4237ddf44fed963b2497e39c0c30
Autor:
Alexander Schnitzler, Andreas Gratz, Andre Bollacke, Michael Weyrich, Uwe Kuckländer, Bernhard Wünsch, Claudia Götz, Karsten Niefind, Joachim Jose
Publikováno v:
Pharmaceuticals, Vol 11, Iss 1, p 23 (2018)
Human protein kinase CK2 is an emerging target for neoplastic diseases. Potent lead structures for human CK2 inhibitors are derived from dibenzofuranones. Two new derivatives, 7,9-dichloro-1,2-dihydro-8-hydroxy-4-[(4-methoxyphenylamino)-methylene]dib
Externí odkaz:
https://doaj.org/article/e600547616ff4022ba3097e5bc9ea5e6
Autor:
Abdelhamid Nacereddine, Andre Bollacke, Eszter Róka, Christelle Marminon, Zouhair Bouaziz, Ferenc Fenyvesi, Ildikó Katalin Bácskay, Joachim Jose, Florent Perret, Marc Le Borgne
Publikováno v:
Pharmaceuticals, Vol 11, Iss 1, p 10 (2018)
Since the approval of imatinib in 2001, kinase inhibitors have revolutionized cancer therapies. Inside this family of phosphotransferases, casein kinase 2 (CK2) is of great interest and numerous scaffolds have been investigated to design CK2 inhibito
Externí odkaz:
https://doaj.org/article/6a035e87689e4152973bb3407ecd5675
Autor:
Christian Nienberg, Claudia Garmann, Andreas Gratz, Andre Bollacke, Claudia Götz, Joachim Jose
Publikováno v:
Pharmaceuticals, Vol 10, Iss 1, p 6 (2017)
Human protein kinase CK2 has emerged as promising target for the treatment of neoplastic diseases. The vast majority of kinase inhibitors known today target the ATP binding site, which is highly conserved among kinases and hence leads to limited sele
Externí odkaz:
https://doaj.org/article/b394dc6f196b47afa0d2e04c9dd1395a
Autor:
Joachim Jose, Ildikó Bácskay, Andre Bollacke, Zouhair Bouaziz, Ferenc Fenyvesi, Florent Perret, Christelle Marminon, Eszter Róka, Abdelhamid Nacereddine, Marc Le Borgne
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 11, Iss 1, p 10 (2018)
Pharmaceuticals, MDPI, 2018, 11 ((1)10), ⟨10.3390/ph11010010⟩
Pharmaceuticals; Volume 11; Issue 1; Pages: 10
Pharmaceuticals, Vol 11, Iss 1, p 10 (2018)
Pharmaceuticals, MDPI, 2018, 11 ((1)10), ⟨10.3390/ph11010010⟩
Pharmaceuticals; Volume 11; Issue 1; Pages: 10
International audience; Since the approval of imatinib in 2001, kinase inhibitors have revolutionized cancer therapies. Inside this family of phosphotransferases, casein kinase 2 (CK2) is of great interest and numerous scaffolds have been investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63b90c77698861ff227a63fa76cbbd6
Autor:
Christoph G. W. Gertzen, Jean Guillon, Holger Gohlke, Zouhair Bouaziz, Laurent Ettouati, Jean-Guy Delcros, Noël Pinaud, Marc Le Borgne, Faten Alchab, Joachim Jose, Mathieu Marchivie, Andre Bollacke, Bernard Fenet
Publikováno v:
Pharmaceuticals, Vol 8, Iss 2, Pp 279-302 (2015)
Pharmaceuticals
Pharmaceuticals, 2015, 8 (2), pp.279-302. ⟨10.3390/ph8020279⟩
Volume 8
Issue 2
Pages 279-302
Pharmaceuticals, MDPI, 2015, 8 (2), pp.279-302. ⟨10.3390/ph8020279⟩
Pharmaceuticals
Pharmaceuticals, 2015, 8 (2), pp.279-302. ⟨10.3390/ph8020279⟩
Volume 8
Issue 2
Pages 279-302
Pharmaceuticals, MDPI, 2015, 8 (2), pp.279-302. ⟨10.3390/ph8020279⟩
International audience; Due to their system of annulated 6-5-5-6-membered rings, indenoindoles have sparked great interest for the design of ATP-competitive inhibitors of human CK2. In the present study, we prepared twenty-one indeno[1,2-b]indole der
Publikováno v:
Proceedings of 1st International Electronic Conference on Medicinal Chemistry.
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 121
Human protein kinase CK2 is an emerging target for the development of novel anti-cancer therapeutics. CK2 is a tetramer composed of two catalytically active α- and/or α'-subunits, bound to a dimer of the regulatory β-subunit. Inhibitors targeting
Autor:
Claudia Götz, Karsten Niefind, Joachim Jose, Michael Weyrich, Bernhard Wünsch, Uwe Kuckländer, Andreas Gratz, Andre Bollacke, Alexander Schnitzler
Publikováno v:
'Pharmaceuticals ', vol: 11, pages: 23-1-23-24 (2018)
Pharmaceuticals
Pharmaceuticals, Vol 11, Iss 1, p 23 (2018)
Pharmaceuticals; Volume 11; Issue 1; Pages: 23
Pharmaceuticals
Pharmaceuticals, Vol 11, Iss 1, p 23 (2018)
Pharmaceuticals; Volume 11; Issue 1; Pages: 23
Human protein kinase CK2 is an emerging target for neoplastic diseases. Potent lead structures for human CK2 inhibitors are derived from dibenzofuranones. Two new derivatives, 7,9-dichloro-1,2-dihydro-8-hydroxy-4-[(4-methoxyphenylamino)-methylene]dib
Autor:
Zouhair Bouaziz, Gro Gausdal, Pascal Sonnet, Andre Bollacke, Joachim Jose, Attilio Di Pietro, Matthias U. Kassack, Catherine Mullié, Samar Issa, Andreas Gratz, Stein Ove Døskeland, Jacques Gentili, Camille Desgrouas, Lars Herfindal, Glaucio Valdameri, Marc Le Borgne, Milad Baitiche, Nicolas Taudon
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry
Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30 (2), pp.180-188. ⟨10.3109/14756366.2014.899594⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2015, 30 (2), pp.180-188. ⟨10.3109/14756366.2014.899594⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30 (2), pp.180-188. ⟨10.3109/14756366.2014.899594⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2015, 30 (2), pp.180-188. ⟨10.3109/14756366.2014.899594⟩
Four series of carbazole derivatives, including N-substituted-hydroxycarbazoles, oxazinocarbazoles, isoxazolocarbazolequinones, and pyridocarbazolequinones, were studied using diverse biological test methods such as a CE-based assay for CK2 activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53eb90ea3a51b4c1641c44d847ac0668
https://hal.science/hal-01683306
https://hal.science/hal-01683306